A preliminary assessment of the acute and subchronic toxicity profile of Phase2

An α-amylase inhibitor

Kuzhuvelil B. Harikumar, Aranjany M. Jesil, Mandumpal C. Sabu, Ramadasan Kuttan

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Phase2®, which has been reported to reduce body weight by its inhibition of α-amylase, was evaluated for toxicity in young adult male and female Wistar rats (10 animals/dose group). Evaluations included mortality, change in body weight, food consumption pattern, organ weight, and other adverse side reactions as well as hematological, biochemical, and histopathological analyses. Acute toxicity was determined after a single dose of Phase2 by oral gavage at doses of 5.0, 1.0, and 0.5 g/kg body weight. Animals were sacrificed on fourteen days after Phase2 administration. Subchronic toxicity was determined by administering Phase2 daily for 90 days to rats, at doses of 1.0, 0.5, and 0.2 g/kg body weight. These animals were sacrificed on day 90. Acute and subchronic administration of Phase2 did not produce any adverse reactions or any significant change in the loss of body weight as compared to untreated controls, organ weight, and mortality. Administration of Phase2 did not alter the hepatic and renal function, and did not produce any change in the hematological parameters and in lipid profile. Subchronic administration produced a reduction in the food consumption after 77 days (1.0 g/kg body weight). These data indicate that acute and subchronic administration of Phase2 did not produce any toxicity to rats as evident from weight change, mortality, and limited biochemical and histopathological analyses.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalInternational Journal of Toxicology
Volume24
Issue number2
DOIs
Publication statusPublished - 01-03-2005

Fingerprint

Amylases
Toxicity
Body Weight
Rats
Animals
Organ Size
Mortality
Food
Body Weight Changes
Wistar Rats
Young Adult
Kidney
Lipids
Weights and Measures
Liver

All Science Journal Classification (ASJC) codes

  • Toxicology

Cite this

Harikumar, Kuzhuvelil B. ; Jesil, Aranjany M. ; Sabu, Mandumpal C. ; Kuttan, Ramadasan. / A preliminary assessment of the acute and subchronic toxicity profile of Phase2 : An α-amylase inhibitor. In: International Journal of Toxicology. 2005 ; Vol. 24, No. 2. pp. 95-102.
@article{e719f6ba9cbd4312b4fd2c349ef2b7fd,
title = "A preliminary assessment of the acute and subchronic toxicity profile of Phase2: An α-amylase inhibitor",
abstract = "Phase2{\circledR}, which has been reported to reduce body weight by its inhibition of α-amylase, was evaluated for toxicity in young adult male and female Wistar rats (10 animals/dose group). Evaluations included mortality, change in body weight, food consumption pattern, organ weight, and other adverse side reactions as well as hematological, biochemical, and histopathological analyses. Acute toxicity was determined after a single dose of Phase2 by oral gavage at doses of 5.0, 1.0, and 0.5 g/kg body weight. Animals were sacrificed on fourteen days after Phase2 administration. Subchronic toxicity was determined by administering Phase2 daily for 90 days to rats, at doses of 1.0, 0.5, and 0.2 g/kg body weight. These animals were sacrificed on day 90. Acute and subchronic administration of Phase2 did not produce any adverse reactions or any significant change in the loss of body weight as compared to untreated controls, organ weight, and mortality. Administration of Phase2 did not alter the hepatic and renal function, and did not produce any change in the hematological parameters and in lipid profile. Subchronic administration produced a reduction in the food consumption after 77 days (1.0 g/kg body weight). These data indicate that acute and subchronic administration of Phase2 did not produce any toxicity to rats as evident from weight change, mortality, and limited biochemical and histopathological analyses.",
author = "Harikumar, {Kuzhuvelil B.} and Jesil, {Aranjany M.} and Sabu, {Mandumpal C.} and Ramadasan Kuttan",
year = "2005",
month = "3",
day = "1",
doi = "10.1080/10915810590936364",
language = "English",
volume = "24",
pages = "95--102",
journal = "International Journal of Toxicology",
issn = "1091-5818",
publisher = "SAGE Publications Inc.",
number = "2",

}

A preliminary assessment of the acute and subchronic toxicity profile of Phase2 : An α-amylase inhibitor. / Harikumar, Kuzhuvelil B.; Jesil, Aranjany M.; Sabu, Mandumpal C.; Kuttan, Ramadasan.

In: International Journal of Toxicology, Vol. 24, No. 2, 01.03.2005, p. 95-102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A preliminary assessment of the acute and subchronic toxicity profile of Phase2

T2 - An α-amylase inhibitor

AU - Harikumar, Kuzhuvelil B.

AU - Jesil, Aranjany M.

AU - Sabu, Mandumpal C.

AU - Kuttan, Ramadasan

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Phase2®, which has been reported to reduce body weight by its inhibition of α-amylase, was evaluated for toxicity in young adult male and female Wistar rats (10 animals/dose group). Evaluations included mortality, change in body weight, food consumption pattern, organ weight, and other adverse side reactions as well as hematological, biochemical, and histopathological analyses. Acute toxicity was determined after a single dose of Phase2 by oral gavage at doses of 5.0, 1.0, and 0.5 g/kg body weight. Animals were sacrificed on fourteen days after Phase2 administration. Subchronic toxicity was determined by administering Phase2 daily for 90 days to rats, at doses of 1.0, 0.5, and 0.2 g/kg body weight. These animals were sacrificed on day 90. Acute and subchronic administration of Phase2 did not produce any adverse reactions or any significant change in the loss of body weight as compared to untreated controls, organ weight, and mortality. Administration of Phase2 did not alter the hepatic and renal function, and did not produce any change in the hematological parameters and in lipid profile. Subchronic administration produced a reduction in the food consumption after 77 days (1.0 g/kg body weight). These data indicate that acute and subchronic administration of Phase2 did not produce any toxicity to rats as evident from weight change, mortality, and limited biochemical and histopathological analyses.

AB - Phase2®, which has been reported to reduce body weight by its inhibition of α-amylase, was evaluated for toxicity in young adult male and female Wistar rats (10 animals/dose group). Evaluations included mortality, change in body weight, food consumption pattern, organ weight, and other adverse side reactions as well as hematological, biochemical, and histopathological analyses. Acute toxicity was determined after a single dose of Phase2 by oral gavage at doses of 5.0, 1.0, and 0.5 g/kg body weight. Animals were sacrificed on fourteen days after Phase2 administration. Subchronic toxicity was determined by administering Phase2 daily for 90 days to rats, at doses of 1.0, 0.5, and 0.2 g/kg body weight. These animals were sacrificed on day 90. Acute and subchronic administration of Phase2 did not produce any adverse reactions or any significant change in the loss of body weight as compared to untreated controls, organ weight, and mortality. Administration of Phase2 did not alter the hepatic and renal function, and did not produce any change in the hematological parameters and in lipid profile. Subchronic administration produced a reduction in the food consumption after 77 days (1.0 g/kg body weight). These data indicate that acute and subchronic administration of Phase2 did not produce any toxicity to rats as evident from weight change, mortality, and limited biochemical and histopathological analyses.

UR - http://www.scopus.com/inward/record.url?scp=20544453094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20544453094&partnerID=8YFLogxK

U2 - 10.1080/10915810590936364

DO - 10.1080/10915810590936364

M3 - Article

VL - 24

SP - 95

EP - 102

JO - International Journal of Toxicology

JF - International Journal of Toxicology

SN - 1091-5818

IS - 2

ER -